Peptides show promise for diagnosing and treating pancreatic cancer, pancreatitis, and diabetes

Pancreatic diseases such as pancreatic cancer, pancreatitis, and diabetes represent significant diagnostic and therapeutic challenges. Current treatment modalities often lack the specificity required for effective intervention, leading to suboptimal patient outcomes and considerable systemic side effects. Peptides offer a compelling alternative due to their inherent high binding affinity, minimal immunogenicity, and precise target specificity. These properties make them ideal candidates for developing targeted diagnostic probes and therapeutic agents that can address critical gaps in early detection and effective treatment across these complex and often devastating conditions.

This comprehensive review critically examines recent advancements in peptide-based strategies for various pancreatic disorders, including inflammatory conditions, metabolic dysfunctions, and notably, pancreatic cancer. The authors delineate the evolution of peptide therapeutics, emphasizing rational drug design approaches such as backbone cyclization and N-methylation to enhance metabolic stability. They also cover computational methodologies like molecular docking and AI-driven affinity maturation to optimize target engagement. The review surveys current clinical trials aimed at translating these engineered peptides into clinical applications, while evaluating their efficacy and biosafety profiles in preclinical models.

The review highlights key innovations in peptide design, including strategies to enhance metabolic stability through backbone cyclization and N-methylation, alongside computational optimization via molecular docking and AI-driven affinity maturation. These advancements are crucial for improving peptide pharmacokinetics and target specificity. The discussion emphasizes the development of peptide probes for early diagnostic detection of pancreatic disorders, offering a non-invasive and highly specific approach. Furthermore, peptide-drug conjugates are presented as a promising avenue for targeted therapeutic intervention, demonstrating efficacy in preclinical models. The authors survey current clinical trials, underscoring the active translation of these engineered peptides towards clinical applications for pancreatic cancer, pancreatitis, and diabetes. The review concludes by outlining future trajectories necessitating advanced AI-integrated design frameworks and robust clinical validation to accelerate bench-to-bedside translation.

Peptide probes are emerging as crucial tools for early diagnostic detection of pancreatic disorders, while peptide-drug conjugates demonstrate potential for targeted therapeutic intervention.